一种具有放射增敏和免疫激活作用的多功能靶向纳米递送系统用于胶质母细胞瘤
针对胶质母细胞瘤(GBM)的放射抵抗、血脑屏障(BBB)限制药物递送及免疫豁免问题,研究设计了两种靶向纳米颗粒:A2-CL/Dbait NPs用于放射增敏,A2-PLGA-PEG-Mal/anti-OX40 NPs用于捕获肿瘤来源蛋白抗原并发挥抗OX40免疫调节作用。两种纳米颗粒在实验模型中显示出良好靶向性和低毒性,联合常规放疗可显著延长小鼠生存时间并显著缩小肿瘤。
要点
- A2-CL/Dbait NPs与A2-PLGA-PEG-Mal/anti-OX40 NPs在实验模型中均显示良好靶向性和低毒性。
- 两种纳米颗粒联合应用可显著延长GBM小鼠生存时间并显著缩小肿瘤。
- 该策略旨在间接利用高剂量照射的免疫刺激效益,同时避免高剂量放疗的脑损伤风险。
核心结论
- 将创新纳米颗粒与常规放疗结合可有效应对GBM治疗中的关键挑战,是迈向更有效、更安全治疗方案的重要一步。
研究设计与样本
- 研究设计了两种靶向纳米颗粒:阳离子脂质体纳米颗粒与Dbait相互作用(A2-CL/Dbait NPs)用于放射增敏;PLGA-PEG-Mal纳米颗粒偶联OX40抗体(A2-PLGA-PEG-Mal/anti-OX40 NPs)用于捕获肿瘤来源蛋白抗原并发挥抗OX40免疫调节作用。
- Angiopep-2(A2)被证明具有满意的血脑屏障和脑靶向性;Dbait是一种小分子,可劫持DNA双链断裂(DSB)修复蛋白使癌细胞对放射更敏感。
- 在实验模型中对两种纳米颗粒的靶向性和毒性进行了评价,并评估了A2-CL/Dbait NPs与A2-PLGA-PEG-Mal/anti-OX40 NPs联合对GBM小鼠生存时间和肿瘤缩小的影响。
主要发现
- 两种纳米颗粒在实验模型中均显示出良好的靶向性和低毒性。
- A2-CL/Dbait NPs与A2-PLGA-PEG-Mal/anti-OX40 NPs联合应用导致GBM小鼠生存时间显著延长和肿瘤显著缩小。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM), the most common primary brain malignancy in adults, is notoriously difficult to treat due to several factors: tendency to be radiation resistant, the presence of the blood brain barrier (BBB) which limits drug delivery and immune-privileged status which hampers effective immune responses. Traditionally, high-dose irradiation (8 Gy) is known to effectively enhance anti-tumor immune responses, but its application is limited by the risk of severe brain damage. Currently, conventional dose segmentation (2 Gy) is the standard radiotherapy method, which does not fully exploit the potential of high-dose irradiation for immune activation. The hypothesis of our study posits that instead of directly applying high doses of radiation, which is risky, a strategy could be developed to harness the immune-stimulating benefits of high-dose irradiation indirectly. This involves using nanoparticles to enhance antigen presentation and immune responses in a safer manner. Angiopep-2 (A2) was proved a satisfactory BBB and brain targeting and Dbait is a small molecule that hijack DNA double strand break damage (DSB) repair proteins to make cancer cells more sensitive to radiation. In view of that, the following two nanoparticles were designed to combine immunity of GBM, radiation resistance and BBB innovatively. One is cationic liposome nanoparticle interacting with Dbait (A2-CL/Dbait NPs) for radiosensitization effect; the other is PLGA-PEG-Mal nanoparticle conjugated with OX40 antibody (A2-PLGA-PEG-Mal/anti-OX40 NPs) for tumor-derived protein antigens capture and optimistic immunoregulatory effect of anti-OX40 (which is known to enhance the activation and proliferation T cells). Both types of nanoparticles showed favorable targeting and low toxicity in experimental models. Specifically, the combination of A2-CL/Dbait NPs and A2-PLGA-PEG-Mal/anti-OX40 NPs led to a significant extension in the survival time and a significant tumor shrinkage of mice with GBM. The study demonstrates that combining these innovative nanoparticles with conventional radiotherapy can effectively address key challenges in GBM treatment. It represents a significant step toward more effective and safer therapeutic options for GBM patients.
引用
- Wen X, Shao Z, Chen X, et al. A multifunctional targeted nano-delivery system with radiosensitization and immune activation in glioblastoma. Radiat Oncol. 2024. PMID: 39267113. doi:10.1186/s13014-024-02511-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。